Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies

Management of advanced colorectal cancer: state of the art

“…Following the regulatory approval of bevacizumab in 2004, TREE-2 was initiated with the aim of evaluating the benefits of bevacizumab in combination with the same regimens. Cross-study comparison suggested that the addition of bevacizumab improved the RR and median time to progression in each arm of the study (Hochster et al, 2005(Hochster et al, , 2006. Overall survival data are eagerly awaited.…”

The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents

“…Bevacizumab does have its own specific safety profile including common and easily manageable adverse events such as hypertension, proteinuria, and mild bleeding and also less common but more serious events such as arterial thromboembolic events, wound healing complications, and serious bleeding events (55)(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66)(67). Rare cases of gastrointestinal perforation have been observed (55).…”

Update on Capecitabine in Colorectal Cancer

“…In the randomized phase II TREE- [24]. The overall incidence of grade 3-4 adverse events was similar on FOLFOX and bFOL arms; however, a greater number of grade 3 neutropenia occurred on the FOLFOX arm (27.8% vs. 10.5%).…”

“…Such data underpin the TREE-2 trial in which first-line patients are randomized to bevacizumab plus FOLFOX, bFOL, or CapOx [24,33]. Preliminary data suggest that the combination with bevacizumab does not increase the overall toxicity of CapOx, nor does it have any impact on the rate of thrombosis.…”